10.04.2012 - Amgen said it will buy privately held KAI Pharmaceuticals for $315 million to gain access to an experimental treatment for a common complication suffered by chronic kidney disease...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)